BRPI0921341A2 - tratamento de leucemia linfoblástica aguda pediátrica - Google Patents

tratamento de leucemia linfoblástica aguda pediátrica

Info

Publication number
BRPI0921341A2
BRPI0921341A2 BRPI0921341A BRPI0921341A BRPI0921341A2 BR PI0921341 A2 BRPI0921341 A2 BR PI0921341A2 BR PI0921341 A BRPI0921341 A BR PI0921341A BR PI0921341 A BRPI0921341 A BR PI0921341A BR PI0921341 A2 BRPI0921341 A2 BR PI0921341A2
Authority
BR
Brazil
Prior art keywords
treatment
lymphoblastic leukemia
acute lymphoblastic
pediatric acute
pediatric
Prior art date
Application number
BRPI0921341A
Other languages
English (en)
Inventor
Gerhard Zugmaier
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BRPI0921341A2 publication Critical patent/BRPI0921341A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0921341A 2008-11-07 2009-11-06 tratamento de leucemia linfoblástica aguda pediátrica BRPI0921341A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
BRPI0921341A2 true BRPI0921341A2 (pt) 2016-04-26

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921341A BRPI0921341A2 (pt) 2008-11-07 2009-11-06 tratamento de leucemia linfoblástica aguda pediátrica

Country Status (27)

Country Link
US (2) US20110262440A1 (pt)
EP (4) EP3594237A1 (pt)
JP (2) JP5798036B2 (pt)
KR (1) KR101695329B1 (pt)
CN (2) CN106390114A (pt)
AU (1) AU2009313039B2 (pt)
BR (1) BRPI0921341A2 (pt)
CA (1) CA2742242C (pt)
CY (3) CY1116160T1 (pt)
DK (3) DK2344539T3 (pt)
ES (3) ES2662929T3 (pt)
HK (1) HK1255590B (pt)
HR (3) HRP20150400T1 (pt)
HU (3) HUE046222T2 (pt)
IL (1) IL212651A (pt)
LT (2) LT2918604T (pt)
MX (1) MX2011002931A (pt)
NO (1) NO2918604T3 (pt)
NZ (1) NZ591312A (pt)
PL (3) PL3330293T3 (pt)
PT (3) PT2344539E (pt)
RS (3) RS53980B1 (pt)
RU (3) RU2536933C2 (pt)
SG (1) SG195549A1 (pt)
SI (3) SI2918604T1 (pt)
SM (3) SMT201800149T1 (pt)
WO (1) WO2010052013A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CN106390114A (zh) * 2008-11-07 2017-02-15 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
EP2386062B1 (en) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN105073776B (zh) * 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
FI3531133T3 (fi) 2014-05-30 2023-11-02 Amgen Res Munich Gmbh Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
EP3175244A4 (en) * 2014-07-30 2018-06-13 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN107635578A (zh) * 2015-02-05 2018-01-26 Stc.Unm 公司 抗前‑bcr拮抗剂和方法
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
AU2016263464B2 (en) * 2015-05-20 2021-12-23 Amgen Research (Munich) Gmbh B-cell depletion as a diagnostic marker
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
US20170174781A1 (en) * 2015-12-22 2017-06-22 Regeneron Pharmaceuticals, Inc. Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
CA3017743A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
MX2018014911A (es) * 2016-06-06 2019-08-12 Juno Therapeutics Inc Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas.
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
KR102700015B1 (ko) * 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
US20220098324A1 (en) * 2019-01-30 2022-03-31 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP4294837A1 (en) 2021-02-16 2023-12-27 Children's Health Care d/b/a Children's Minnesota Methods for treating b-all by administering a pre-bcr complex antagonist
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
KR20240099263A (ko) 2021-10-15 2024-06-28 암젠 리서치 (뮌헨) 게엠베하 Cd19 결합 t 세포 관여 항체의 피하 투여
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
KR100508289B1 (ko) * 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
SI1976886T1 (sl) * 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
CN106390114A (zh) * 2008-11-07 2017-02-15 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
NZ593594A (en) * 2009-01-19 2013-08-30 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG172391A1 (en) * 2009-01-19 2011-07-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2763633A1 (en) * 2009-05-27 2010-12-02 Gary T. Wang Pyrimidine inhibitors of kinase activity
CN102695702A (zh) * 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
BR112012009778A2 (pt) * 2009-10-27 2017-06-13 Micromet Ag regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3

Also Published As

Publication number Publication date
CY1122428T1 (el) 2021-01-27
SI2344539T1 (sl) 2015-06-30
JP5798036B2 (ja) 2015-10-21
CY1120022T1 (el) 2018-12-12
PL3330293T3 (pl) 2020-02-28
LT3330293T (lt) 2019-10-10
SI3330293T1 (sl) 2019-10-30
EP3330293B1 (en) 2019-07-24
RU2536933C2 (ru) 2014-12-27
HRP20191715T1 (hr) 2019-12-13
RU2677324C2 (ru) 2019-01-16
CN102209729A (zh) 2011-10-05
RU2014141180A3 (pt) 2018-06-09
JP2012508163A (ja) 2012-04-05
SG195549A1 (en) 2013-12-30
US20230235053A1 (en) 2023-07-27
CN102209729B (zh) 2016-05-25
EP3330293A1 (en) 2018-06-06
HK1215258A1 (en) 2016-08-19
ES2748126T3 (es) 2020-03-13
EP2344539A1 (en) 2011-07-20
ES2662929T3 (es) 2018-04-10
WO2010052013A1 (en) 2010-05-14
RU2014141180A (ru) 2016-05-10
DK2918604T3 (en) 2018-03-19
KR101695329B1 (ko) 2017-01-23
RS53980B1 (sr) 2015-10-30
HRP20180426T1 (hr) 2018-04-20
ES2535257T3 (es) 2015-05-07
DK3330293T3 (da) 2019-10-07
CA2742242A1 (en) 2010-05-14
KR20110091669A (ko) 2011-08-12
CN106390114A (zh) 2017-02-15
NZ591312A (en) 2012-09-28
LT2918604T (lt) 2018-03-26
SMT201500104B (it) 2015-07-09
DK2344539T3 (en) 2015-05-04
EP2918604B1 (en) 2017-12-20
RS59348B1 (sr) 2019-10-31
EP2344539B1 (en) 2015-02-11
CA2742242C (en) 2023-01-10
EP3594237A1 (en) 2020-01-15
IL212651A0 (en) 2011-07-31
JP2015232023A (ja) 2015-12-24
SMT201900546T1 (it) 2019-11-13
SI2918604T1 (en) 2018-04-30
MX2011002931A (es) 2011-04-11
AU2009313039A1 (en) 2010-05-14
EP2918604A1 (en) 2015-09-16
PT3330293T (pt) 2019-10-18
CY1116160T1 (el) 2017-02-08
RU2736802C2 (ru) 2020-11-20
PL2918604T3 (pl) 2018-05-30
JP6130451B2 (ja) 2017-05-17
PT2344539E (pt) 2015-04-01
RS56989B1 (sr) 2018-05-31
NO2918604T3 (pt) 2018-05-19
HK1255590B (en) 2020-07-10
RU2011122827A (ru) 2012-12-20
RU2018144313A (ru) 2020-06-15
AU2009313039B2 (en) 2015-06-18
HRP20150400T1 (hr) 2015-05-08
PL2344539T3 (pl) 2015-07-31
HUE036922T2 (hu) 2018-08-28
PT2918604T (pt) 2018-03-02
IL212651A (en) 2015-03-31
HUE046222T2 (hu) 2020-02-28
HK1158667A1 (en) 2012-07-20
RU2018144313A3 (pt) 2020-06-15
SMT201800149T1 (it) 2018-05-02
HUE025452T2 (en) 2016-05-30
US20110262440A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
HUE036922T2 (hu) Pediátriai akut limfoblaszt leukémia kezelése
BRPI0910854A2 (pt) métodos de tratamento
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0917567A2 (pt) tratamento de doença respiratória
EP2127144A4 (en) COGNITIVE MULTI-USER OFDMA
DK2330887T3 (da) Behandlingsindretning
BRPI0912683A2 (pt) tratamento de tumores metastáticos
DK2173831T3 (da) Brøndbehandling
DE502008000740D1 (de) Rollosystem
EP3381471C0 (en) PAIN TREATMENT
FI20085693A0 (fi) Biosignaalin prosessointi
HRP20150373T1 (xx) Dijagnostiäśke metode b-staniäśnog limfoma
EP2368499A4 (en) TREATMENT INSTRUMENT
HUE038563T2 (hu) Rák kezelési eljárás
LTC2066352I2 (lt) Išsėtinės sklerozės (MS) gydymas kampatu-1H
HRP20160577T1 (hr) Liječenje osteoartritisa
DE602007013310D1 (de) Hochfrequenzbehandlungsinstrument
BRPI0815051A2 (pt) Tratamento de tumores pediátricos
BRPI0922216A2 (pt) tratamento para glomerulonefrite
GB0723100D0 (en) Treatment of HFnEF
BRPI0815772A2 (pt) Tratamento de câncer de pulmão
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AMGEM RESEARCH (MUICH) GMBH (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]